24.09.2012 - Syngenta is set to buy two biotech companies: The Swiss firm is willing to pay up about €500m for seed maker Devgen NV and Pasteuria Biosciences.
Syngenta announced an offer to acquire all outstanding shares of Devgen NV at a price of €16 in cash per share, valuing the Belgian hybrid rice seed producer at €403m in total. The offer price represents a premium of 70% to Devgen's closing price on NYSE Euronext Brussels on 20 September 2012, the day before the tender offer was made public.
The Belgian group posted sales of €25.5m and an operational loss of €6.3m in 2011. Created in 1997, the company employs 250 people and among its products is a hybrid rice developed for India and South-east Asia. The asset will have a “very significant impact” on Syngenta’s $500 million rice business, Chief Operating Officer Davor Pisk said in an interview today. "We are also buying their competence in RNAi technology which are relevant for us across a broad range of crops“, added Syngenta spokeswoman Jennifer Gough.
This is Syngenta's second deal announced within a week. Only days before, Swiss company revealed its plans to acquire Pasteuria Biosciences for €87m. Since 2011, Syngenta and the US company have had an exclusive global technology partnership to develop and commercialise biological products to control plant-parasitic nematodes, using the naturally occurring soil bacteria Pasteuria spp.
With its acquisition strategy, Syngenta reacts to the increasingly fierce competition with agribusiness companies Bayer and BASF both of Germany. BASF recently announced the intention to buy Becker Underwood for €785m, while Bayer decided months ago to purchase US-based AgraQuest for €340m plus milestone payments.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more